Posters
Presenting Author Academic/Professional Position
Medical Student
Academic Level (Author 1)
Medical Student
Academic Level (Author 2)
Faculty
Discipline/Specialty (Author 2)
Immunology and Microbiology
Academic Level (Author 3)
Faculty
Academic Level (Author 4)
Faculty
Discipline/Specialty (Author 4)
Immunology and Microbiology
Academic Level (Author 5)
Faculty
Discipline/Specialty (Author 5)
Internal Medicine
Presentation Type
Poster
Discipline Track
Biomedical Science
Abstract Type
Research/Clinical
Abstract
Background: Cervical cancer is the fourth most common cancer in adult females globally and the second most common cancer in females between the ages of 15 and 44. The alanine-serine- cysteine transporter 2, ASCT2 (solute carrier family 1 member 5, SLC1A5), is a major transporter of the amino acid, glutamine. SLC1A5 expression is associated with the progression of multiple types of tumors, including liver, lung, breast, colon and head and neck cancer. However, the biological significance of SLC1A5 cervical cancer has not been systematically and comprehensively investigated. Using deep data mining and transcriptomics analyses, in this study, we investigated the significance of SLC1A5 expression and its association with cervical cancer prognosis.
Methods: SLC1A5 mRNA expression in cervical cancer was examined using the Cancer Genome Atlas (TCGA), the Genotype Tissue Expression Atlas (GTEx), the Tumor Immune Estimation Resource (TIMER), and the UALCAN databases to examine the relationship between the expression of SLC1A5 and the clinicopathological characteristics of cervical cancer. The genetic alterations and frequency of SLC1A5 were analyzed using the cBioPortal and COSMIC databases. The correlations between SLC1A5 and tumor-infiltrating immune cells were examined using the TIMER 2.0, TISIDB, and GEPIA databases. The data processing analysis is based on the R language. LinkedOmics was used for SLC1A5 co-expression network analysis. Drug sensitivity was analyzed through the GDSC and CTRP databases. Results: The SLC1A5 mRNA expression was upregulated in cervical cancer samples as compared to normal cervical tissues. For the cancer stages, ages, races, patients weight, histopathological subtype, and nodal metastasis status there existed significant difference in the expression of SLC1A5 among different groups by mining of the UALCAN database. The mutation landscape analysis confirms that SLC1A5 genetic alterations reached 3%, of which missense substitutions accounted for the highest proportion of 48.77%. The findings of the TIMER analysis indicated a correlation between immune cell infiltration and SLC1A5 copy number alterations (CNA). The expression level of SLC1A5 was positively correlated with the infiltration level of CD4+T cells, Neutrophil, and dendritic cell but negatively correlated with CD8+ T cells, B cells and macrophages infiltration. Additionally, SLC1A5 expression was also found to be associated with certain immunosuppressive cells, chemokines, and receptors. Through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, SLC1A5 expression was found to be closely related to some immune pathways, including proteasome, DNA replication, ribosome biogenesis and DNA replication. Among all co-expressed genes, NOX3 and SHMT2 had a high co-expression efficient. Furthermore, SLC1A5 presented a positive association with sensitivity to GDSC and CTRP drugs.
Conclusion: Our observation demonstrates that SLC1A5 was highly expressed in cervical cancer tissues and is linked to prognosis of cervical cancer patients and tumor immune responses. The present study might be benefit for better understanding the clinical significance of SLC1A5 and provided a potential therapeutic target for cervical cancer in future.
Recommended Citation
O'Brien, Veronica; Kashyap, Vivek; Sharma, Bhuvnesh; Yallapu, Murali; Cobos, Everardo; and Chuahan, Subhash, "Integrative analysis of transcriptomics and clinical data of SLC1A5 in cervical cancer" (2025). Research Symposium. 169.
https://scholarworks.utrgv.edu/somrs/2025/posters/169
Included in
Integrative analysis of transcriptomics and clinical data of SLC1A5 in cervical cancer
Background: Cervical cancer is the fourth most common cancer in adult females globally and the second most common cancer in females between the ages of 15 and 44. The alanine-serine- cysteine transporter 2, ASCT2 (solute carrier family 1 member 5, SLC1A5), is a major transporter of the amino acid, glutamine. SLC1A5 expression is associated with the progression of multiple types of tumors, including liver, lung, breast, colon and head and neck cancer. However, the biological significance of SLC1A5 cervical cancer has not been systematically and comprehensively investigated. Using deep data mining and transcriptomics analyses, in this study, we investigated the significance of SLC1A5 expression and its association with cervical cancer prognosis.
Methods: SLC1A5 mRNA expression in cervical cancer was examined using the Cancer Genome Atlas (TCGA), the Genotype Tissue Expression Atlas (GTEx), the Tumor Immune Estimation Resource (TIMER), and the UALCAN databases to examine the relationship between the expression of SLC1A5 and the clinicopathological characteristics of cervical cancer. The genetic alterations and frequency of SLC1A5 were analyzed using the cBioPortal and COSMIC databases. The correlations between SLC1A5 and tumor-infiltrating immune cells were examined using the TIMER 2.0, TISIDB, and GEPIA databases. The data processing analysis is based on the R language. LinkedOmics was used for SLC1A5 co-expression network analysis. Drug sensitivity was analyzed through the GDSC and CTRP databases. Results: The SLC1A5 mRNA expression was upregulated in cervical cancer samples as compared to normal cervical tissues. For the cancer stages, ages, races, patients weight, histopathological subtype, and nodal metastasis status there existed significant difference in the expression of SLC1A5 among different groups by mining of the UALCAN database. The mutation landscape analysis confirms that SLC1A5 genetic alterations reached 3%, of which missense substitutions accounted for the highest proportion of 48.77%. The findings of the TIMER analysis indicated a correlation between immune cell infiltration and SLC1A5 copy number alterations (CNA). The expression level of SLC1A5 was positively correlated with the infiltration level of CD4+T cells, Neutrophil, and dendritic cell but negatively correlated with CD8+ T cells, B cells and macrophages infiltration. Additionally, SLC1A5 expression was also found to be associated with certain immunosuppressive cells, chemokines, and receptors. Through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, SLC1A5 expression was found to be closely related to some immune pathways, including proteasome, DNA replication, ribosome biogenesis and DNA replication. Among all co-expressed genes, NOX3 and SHMT2 had a high co-expression efficient. Furthermore, SLC1A5 presented a positive association with sensitivity to GDSC and CTRP drugs.
Conclusion: Our observation demonstrates that SLC1A5 was highly expressed in cervical cancer tissues and is linked to prognosis of cervical cancer patients and tumor immune responses. The present study might be benefit for better understanding the clinical significance of SLC1A5 and provided a potential therapeutic target for cervical cancer in future.
